Kornimate/medical-research-clean huggingface dataset:
burnout reduction and engagement app-based trial of headspace (breathe)

Conditions: Burnout, Professional

Summary: the purpose of this research is to develop a mobile app-based intervention to reduce burnout and improve well-being using human-centered design principles and stakeholder feedback.

recent studies of professional burnout among physicians have highlighted urology as a worrisome outlier: 39% of practicing urologists and 64% of urology residents reported high levels of depersonalization and emotional exhaustion. despite the known association of burnout with adverse clinical outcomes, psychological distress, and career dissatisfaction, rigorous studies of physician-focused interventions remain limited. pilot studies of well-being mobile applications (e.g. headspace ®) have demonstrated better outcomes compared to traditionally delivered mindfulness interventions (e.g. in-person guided meditation). nevertheless, a rigorous assessment of the impact of an app-based intervention on burnout is needed. therefore, the present study will assess the effectivity of a mobile app-based intervention to reduce burnout among healthcare professionals.

Eligibility criteria:
inclusion criteria: * being a health-professional at the urology department of mayo clinic, rst * sign the informed consent and agreed to share data from the app to the research team. exclusion criteria: * using an alternate app designed with the same purpose at the beginning, part and/or entire duration of the study. * not provide any data despite being included in the study
a prospective, two-center, single arm phase ii clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules

Conditions: Progression

Summary: a prospective, two-center, single arm phase ii clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules


Eligibility criteria:
inclusion criteria: 1. aged between 18 and 85 years; 2. ggo is diagnosed by lung ct and failure to subside after 3 months (the patient having been re-examined by thin-section ct); 3. the maximum diameter of the ggo is bigger than 8mm and smaller than 3cm; 4. for single ggo: obvious progress was observed in pure ggo or the solid component of mixed ground glass nodules was more than or equal to 2 mm 5. the patients were unable to tolerate the operation for various reasons or multiple grinding glass nodules, operation can not be completely removed; or patients had received surgery in ipsilateral chest 6. the patient is able to understand and comply with the study and has provided written informed consent exclusion criteria: 1. patients who participated in any drug and / or medical device clinical trials within one month before the trial 2. had severe disease conditions 3. allergy to narcotic drugs 4. had other autoimmune disease 5. dementia or cognitive impairment can't cooperate with researchers 6. any local treatment other than ablation was received within 4 weeks before the study
clear sepsis clinical study

Conditions: Sepsis

Summary: to investigate the relationship between initial clearsight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed icu admission) in patients with acute infection and possible sepsis, with a focus on venous blood lactate (\< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dl) and hemodynamic subgroups, using ed patients presenting with minor infections or asthma/copd exacerbations as controls (henceforth referred to as sepsis mimic group).


Eligibility criteria:
venous blood lactate groups inclusion criteria: * ≥ 18 years of age at the time of enrollment * any combination of acute symptoms and signs that the treating ed physician, after initial history and physical examination, attributes to a systemic infection * ed physician confirms likely hospital admission (\> 50%) due to suspicion of infection * ed physician confirms intention to order both blood cultures and venous blood lactate levels * ability to enroll patient and begin clearsight™ monitoring within three (3) hours of ed presentation exclusion criteria: * initial venous blood lactate measured \> 3 hours after ed arrival * pre-existing infection for which patient is being treated with antibiotics as an outpatient * prisoners * pregnant women * any previous medical condition with life expectancy of \< 3 months (patients with esrd and heart failure are not excluded) * dnr or comfort care order preexisting to ed visit or established in the ed * palliative care or hospice consult in the ed * known severe aortic insufficiency * known history of raynaud's disease * poor follow-up candidate in the opinion of the investigator * current or planned enrollment in an investigational trial that in the opinion of the investigator may significantly affect hemodynamic data collection. control sepsis mimic inclusion criteria: * ≥18 years of age at the time of enrollment * presents to the ed with a chief complaint consistent with a minor infection (upper respiratory infection, soft tissue infection, viral infection) or an asthma or copd exacerbation on whom the treating physician is not ordering labs for blood cultures or lactate levels * ability to enroll patient and begin clearsight™ monitoring within three (3) hours of ed presentation. exclusion criteria: * pre-existing infection for which patient is being treated with antibiotics as an outpatient * prisoners * pregnant women * any previous medical condition with life expectancy of \< 3 months (patients with esrd and heart failure are not excluded) * dnr or comfort care order preexisting to ed visit or established in the ed * palliative care or hospice consult in the ed * known severe aortic insufficiency * known history of raynaud's disease * poor follow-up candidate in the opinion of the investigator * current or planned enrollment in an investigational trial that in the opinion of the investigator may significantly affect hemodynamic data collection. * treating physician is planning on ordering either a lactate or blood cultures on the patient.
a study to compare the pharmacokinetics and safety of replenine®-vf, replenine® or other factor ix in haemophilia b

Conditions: Haemophilia B

Summary: the purpose of this study is: * to compare the pharmacokinetics of replenine®-vf and replenine® or any other high purity factor ix concentrate, when given as a bolus dose of 75iu/kg. * to compare the 1st and 2nd pharmacokinetic assessments on replenine®-vf (conducted 3 months apart) and recovery if patients changes batches. * to evaluate replenine®-vf in terms of clinical tolerance and safety in patients with severe haemophilia b.


Eligibility criteria:
inclusion criteria: * patients aged 12 years or over * at least 20 exposures suffering from severe haemophilia b and without inhibitors to factor ix and on replenine® or any other high purity factor ix product exclusion criteria: -
metabolic effects of switching to aripiprazole in patients with bipolar disorders

Conditions: Bipolar Disorders; Metabolic Complication

Summary: the primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.

* reduced treatment adherence due to metabolic side effects * suggested advantages of aripiprazole in metabolic profile over other antipsychotics or mood stabilizers * randomized trial of switch from previous drugs to aripiprazole

Eligibility criteria:
inclusion criteria: * patients with bipolar disorders (i, ii, nos) diagnosed with dsm-iv criteria * age between 18 and 65 * decisional capacity is adequate to provide informed consent or has an authorized appropriate surrogate decision maker. in a syndromal remission state at least for 2 months : cgi - bp ≤ 3 * patients who have exhibited a clinically significant increase in body weight after starting the administration of their current antipsychotic (ie \>7% weight gain) exclusion criteria: * diagnosis of eating disorder, substance abuse, and psychotic disorder * history of neurological and medical illness * pregnant or breast feeding women

Keywords: bipolar disorder metabolic complication aripiprazole weight gain clinical trial antipsychotic metabolic syndrome psychopharmacology open label
trial comparing electric and harmonic scalpel in mastectomy

Conditions: Complication, Postoperative

Summary: prospective trial comparing post-operative complications and seroma formation after mastectomy in patients with breast cancer, using conventional electric scalpel and harmonic scalpel.

the population of this study was formed by women aged older than 18 years old, with breast carcinoma (ductal ou lobular) at any stage, form whom modified radical mastectomy is proposed. patients were excluded if the present blood dyscrasia, collagen diseases, known uncontrolled chronic disease, infections (mammary or axillary, ulcerated tumors and pregnancy. the women were submitted to modified radical mastectomy consecutive allocated in electric scalpel group and the other group with harmonic scalpel. electric scalpels were calibrated at 40 watts of cutting and coagulation power and harmonic scalpel with a gen04 generator calibrated at power levels 3 and 5, using the hp054 handpiece and hf105 curved blade. local postoperative complications analysed were seroma, hematoma, skin necrosis and infection.

Eligibility criteria:
women with breast cancer candidate to a radical mastectomy during the year of 2008. prospective trial with women stratified consecutive. inclusion criteria: * breast carcinoma (ductal or lobular) * modified radical mastectomy was the surgery to be realized exclusion criteria: * not inclusion criteria * blood dyscrasia, collagen diseases, known uncontrolled chronic diseases, infections (mammary or axillary), ulcerated tumors and pregnancy
chemotherapy mfolfirinox in locally advanced or metastatic cholangiocarcinoma

Conditions: Cholangiocarcinoma of the Bile Duct

Summary: the aim of this study was to evaluate the effectiveness of modified folfirinox (mfolfirinox) compared to that of gemcitabine plus oxaliplatin (gemox) for patients with locally advanced or metastatic cca

the aim of this study was to evaluate the effectiveness of modified folfirinox (mfolfirinox) compared to that of gemcitabine plus oxaliplatin (gemox) for patients with locally advanced or metastatic cca

Eligibility criteria:
the inclusion criteria included: patients aged 18-70 years old, regardless of gender; patients with locally advanced or metastatic cca diagnosed by imaging and pathology; modified folfirinox regimen or gemox regimen as first-line treatment; ≥ 1 focus that can be evaluated by imaging examination. exclusion criteria included: incomplete clinical history data; suffering from other malignant tumors within 5 years, except basal cell carcinoma and cervical carcinoma in situ; having received other systemic chemotherapy, targeted therapy, immunotherapy or radiotherapy as first-line treatment; with severe organ dysfunction.
registry on neva vs for cerebral vasospasm management in post sah patients

Conditions: Cerebral Vasospasm; Aneurysmal Subarachnoid Hemorrhage (aSAH)

Summary: a multi-center, observational registry study intended to assess the hde-approved neva vs cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (asah)


Eligibility criteria:
inclusion criteria: 1. age ≥22 2. symptomatic cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage (asah) in the internal carotid artery (ica), middle cerebral artery (mca), anterior cerebral artery (aca), posterior cerebral artery (pca), or basilar artery (ba) 3. vessel dilation procedure was performed with the neva vs 4. subject or legal representative is able and willing to give informed consent within 3 days (72 hours) post-index procedure exclusion criteria: * none

Keywords: vasospasm
increased activity of a renal salt transporter (enac) in diabetic kidney disease

Conditions: Diabetic Nephropathies; Hypertension

Summary: the purpose of the study is to determine whether a diuretic drug called amiloride is capable of increasing renal salt excretion and thereby decrease blood pressure in diabetic patients with kidney disease. our hypothesis states that amiloride is capable of reducing blood pressure in these patients and thus decrease the cardiovascular risk associated with diabetic kidney disease.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * negative pregnancy test at inclusion and taking contraceptive medication * one group with diabetic nephropathy and overt proteinuria * one normoalbuminuric group without nephropathy * creatinine clearance \> 40 ml/min exclusion criteria: * type 2 diabetes * receiving amiloride, glucocorticoids, aldosterone or spironolactone * clinically relevant organic or systemic disease including malignancy

Keywords: diabetic nephropathies hypertension proteinuria albuminuria epithelial sodium channels epithelial sodium channel blockers amiloride
spectral analysis probe to identify glioblastoma cells

Conditions: Glioblastoma

Summary: this is a pilot, observational study to evaluate the intraoperative sensitivity of the chaos wand in detecting tumor tissue with glioblastoma disease.

this is a pilot study to investigate if the chaos wand spectral diagnosis probe can be used to identify glioblastoma (gbm) cancer cells in patients undergoing standard surgical resection. eligible patients who have consented to the use of the chaos wand will be scheduled for surgery as standard cancer care for gbm. during the surgical procedure, the chaos wand spectral diagnosis probe will be utilized. fifteen intraoperative readings and signal recordings of gbm tissue will be taken. the wand will only be used in areas that have already been deemed in need of resection due to gbm disease. each site identified for spectral analysis will be marked. the wand does not come into contact with the brain at any point during this procedure. following surgical resection of the gbm tumor, tissue will be collected from the same 15 sites where the chaos wand was used. the pathology report will be compared with the results of spectral analysis.

Eligibility criteria:
inclusion criteria: 1. male or female and over 18 years of age. 2. patients with histologically proven gbm who are newly diagnosed and eligible to undergo surgical treatment or patients who are suspected of having glioblastoma on pre-operative imaging which is subsequently confirmed by histopathology following tumor resection. 3. patients must be able to understand and willing to sign the informed consent document. exclusion criteria: 1. patients with absence of glioblastoma. 2. patients who are not undergoing tumor resection. 3. patients who have prior brain radiotherapy 4. patients who have prior systemic chemotherapy 5. patients who are not willing to sign the informed consent and agree to participate. 6. patients who are pregnant or nursing

Keywords: spectral diagnosis probe chaos wand spectral analysis optical spectroscopy
crowdsourcing to promote hbv and hcv testing in china

Conditions: Hepatitis; Hepatitis B; Hepatitis C

Summary: this is an online randomized controlled trial (rct) comparing men who have sex with men (msm) exposed to a crowdsourced intervention to msm who did not receive the intervention to determine the effect on hepatitis b virus (hbv) and hepatitis c virus (hcv) testing. participants will be randomly assigned in a 1:1 ratio to intervention or control using a computer-based allocation system. participants will be assessed for primary and secondary outcomes four weeks after randomization.

700 msm will be recruited through social media operated by gay organizations in china. eligible participants will be born biologically male, age 16 years or older, report previous anal sex with another man, and reside in china. men self-reporting previous hbv vaccination, hbv testing, or hcv testing will be excluded. after completing a baseline online survey, participants will be randomly assigned to intervention or control arms with a 1:1 allocation ratio. the intervention will include two components: (1) a multimedia component will deliver two videos and two images promoting hbv and hcv testing developed through a crowdsourcing contest in china. (2) a participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images. the control arm will not view any images or videos and will not be invited to submit suggestions. all participants will be offered reimbursement for hbv and hcv testing costs. the primary outcome is hbv and hcv test uptake confirmed through electronic submission of test report photos within four weeks of enrollment. secondary outcomes include self-reported hbv and hcv test uptake, hbv vaccination uptake, and change in stigma toward people living with hbv measured through a follow-up survey after four weeks. men with primary and secondary outcomes will be calculated using intention to treat and as-exposed analyses and compared using two-sided 95% confidence intervals.

Eligibility criteria:
inclusion criteria: * 16 years of age or older * male * report having had anal sex with another man at least once in the past * currently reside in china * willing to provide working mobile phone number and wechat account exclusion criteria: * previous hbv vaccination * previous hbv testing * previous hcv testing

Keywords: hepatitis hepatitis b hepatitis c men who have sex with men crowdsourcing china testing
self-managed walking improves function

Conditions: Peripheral Arterial Disease; Diabetes Mellitus

Summary: we are conducting a clinical research trial to determine the role of self-managed walking therapy to improve walking ability in patients with diabetes mellitus and peripheral arterial disease (pad). pad, commonly referred to as poor circulation in the legs, is a very common disease in patients with diabetes mellitus. for patients with pad, there is a significant risk for poor walking ability and limb loss. one major treatment for pad is walking therapy but the traditional methods for the delivery of this treatment have required frequent visits to a university or hospital-based site. we will address the role of self-managed walking program, to be conducted at or near the home, to improve limb function.

peripheral arterial disease (pad) is a prevalent illness that affects 12% of u.s adults. diabetes mellitus is one of the strongest atherosclerotic risk factors for this disease. among patients with diabetes mellitus, the prevalence of pad is as high as 29%. an underutilized component of care for pad is walking therapy. walking has specifically been shown to improve functional status in patients with pad and leg symptoms. leg symptoms in pad include intermittent claudication and atypical leg symptoms (leg discomfort other than intermittent claudication). patients with symptomatic pad have impaired lower extremity functioning, which clinically manifests as slower walking speed, reduced walking distance, and lower physical activity levels. these functional deficits often hinder the ability to live independently in the community (e.g., walking to the bus stop in time for the next bus, shopping independently for groceries). reduced physical activity is associated with an increased risk for mobility loss and a higher risk for functional decline with subsequent inability to perform activities of daily living. walking therapy should not be a burden and it should be something that the patient can routinely perform without the need for regular supervision, a treadmill, or to report to the hospital (i.e., self-managed walking therapy). as patients with diabetes mellitus have special needs for self-management behavior (e.g., diet, medication adherence) and, for those with pad, a higher burden of atypical leg symptoms, the role of a self-managed walking program specific to this group of pad patients cannot be overemphasized. thus, this clinical trial has 2 novel aspects: 1) to evaluate the role of self-managed walking therapy for patients with symptomatic pad and 2) to focus on patients with pad and diabetes mellitus.

Eligibility criteria:
inclusion criteria: * age 40 years and older * diabetes mellitus * peripheral arterial disease * leg symptoms exclusion criteria: * myocardial infarction within 3 months of enrollment * inability to walk for exercise secondary to chest pain, dyspnea, or poor balance * prior major amputation

Keywords: walking therapy diabetes mellitus peripheral arterial disease
a randomised, blinded study on laparoscopic mesh reinforcement for chronic groin pain

Conditions: Chronic Groin Pain

Summary: chronic groin pain is a frequent cause for referral to general surgeons. in some cases this pain may be due to the presence of a hernia. however, if on clinical examination there is no palpable lump or bulge, the cause of the pain may be difficult to elucidate. some of these patients may have the diagnosis of sportsman's groin. other names which have been attached to this condition include gilmores groin and sportsmans hernia. these conditions are more commonly associated with sportsmen and women but those who do not play sport may also receive this diagnosis. sportsman's groin is thought to be a syndrome of weakness of the posterior inguinal wall without a clinically recognisable hernia. differing explanations for sportsman's groin include avulsion of the conjoint tendon from the pubic tubercle, weakening of the transversalis fascia, tears in the internal or external oblique, superficial inguinal ring dilatation and abnormalities of the rectus abdominus insertion. there is some evidence that pre peritoneal mesh placement in these patients may be beneficial. the theory being that the mesh prevents pressure transmission to the damages structures, allowing them to heal more rapidly. aim. to assess the potential benefit of pre peritoneal mesh placement using the tapp technique in patients with chronic groin pain.


Eligibility criteria:
inclusion criteria: * groin pain (unilateral or bilateral) for at least 4 months. in this way, patients with temporary symptoms will be excluded from undergoing unnecessary surgery. * tenderness over pubic tubercle or superficial inguinal ring. exclusion criteria: * aged less than 18 years aged more than 50 years - due to increased incidence of sacro-iliac and hip pathology. * bulge, lump or cough impulse consistent with inguinal or femoral hernia on clinical examination. * patients unwilling or unable to provide informed consent. medically unfit for general anaesthetic * pregnant women * diabetes - due to diabetic neuropathy * steroid use * qst suggestive of nerve entrapment.

Keywords: sportsmans groin, gilmores groin